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ABSTRACT 
 
We -analyzed transcriptomic, proteomic and metabolomic profiles of hepatoma cells 
cultivated inside a microfluidic biochip with or without acetaminophen (APAP). 
Without APAP, the results show an adaptive cellular response to the microfluidic 
environment, leading to the induction of anti-oxidative stress and cytoprotective 
pathways. In presence of APAP, calcium homeostasis perturbation, lipid peroxidation 
and cell death are observed. These effects can be attributed to APAP metabolism 
into its highly reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI). . That 
toxicity pathway was confirmed by the detection of GSH-APAP, the large production 
of 2-hydroxybutyrate and 3-hydroxybutyrate, and methionine, cystine, and histidine 
consumption in the treated biochips. Those metabolites have been reported as 
specific biomarkers of hepatotoxicity and glutathione depletion  in the literature. In 
addition, the integration of the metabolomic, transcriptomic and proteomic profiles 
collected allowed a more complete reconstruction of the APAP injury pathways. To 
our knowledge, this work is the first example of a global integration of microfluidic 
biochip data in toxicity assessment. Our results demonstrate the potential of that new 
approach to predictive toxicology.  
 
 
Keywords: Microfluidic biochip, PDMS, liver tissue engineering, predictive 
toxicology, acetaminophen, transcriptomic, proteomic, metabolomic, biomarkers 
identification 
 
 
 
 
 
 
 
 
 
NOMENCLATURE 
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 Superscripts in figures denote information confirmed at  
(1) the gene, protein and metabolite levels,  
(2) at the gene and protein levels,  
(3) at the gene and metabolite levels,  
(4) at the gene level,  
(5) at the protein level,  
(6) at the metabolite level.  
 
Capital letters (G6PD …) refer to genes symbols, 
Chemical species in italics  (as in g6pd or glucose-6-phosphate dehydrogenase…) 
refer to proteins or gene products, 
Species in regular typeface (glucose…) refer to metabolites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
INTRODUCTION 
 
   
 Currently, in vitro cell culture methods for screening molecules  mainly use 
plates (Petri dishes). Hepatocytes are considered to be among the most difficult type 
of cells to maintain in vitro in such systems. However it is essential use hepatocytes 
to understand and model metabolic phenomena (Guillouzo, 2008). That is  why many 
tissue engineering processes have been developed to provide better environments 
for  hepatocytes maintenance and development (Gebhardt, 2003; De Bartolo and 
Bader, 2001; Franklin and Yost, 2000; Guillouzo, 1998; De Kanter et al., 2002). Such  
environments must reproduce, as closely as possible, the in vivo conditions.  Each 
one of the many in vitro hepatic culture systems currently available or in 
developement. can be used to answer toxicology or pharmacology questions, but 
they should be carefullyselected to be able to meet the pursued objectives. 
One such in vitro system, bioartificial organs, seems to be a suitable method 
for reproducing the behavior of an organ or group of organs as well as the conditions 
of in vivo exposure. Bioartificial organs can now take advantage of recent 
developments in microtechnology to produce  systems on a very small scale (Griffith 
and Naughton 2002; Powers et al., 2002; Sivaraman et al., 2005; Chao et al., 2010; 
Prot et al., 2011a; Baudoin et al., 2007; Novik et al., 2010; Baudoin et al., 2011). The 
cellular organization brought about by the micro-topography of these systems and 
their dynamic microfluidic culture conditionsappear to be key features for reproducing 
in vivo environments. These systems can function equally well in closed or open 
circuit modes, and thus simulate either chronic or acute tissue exposures.  
 A variety of approaches are available for describing the behavior and activity 
of cells as they react to stress, such as during exposure to a drug ). Transcriptomic, 
proteomic and metabolomic techniques are part of those (Boverhof et al., 2006). 
Genomic and transcriptomic methods can provide a near-complete analysis of the 
hereditary material of living organisms. Proteomicsassay all the proteins contributing 
to the structure and function of a cellular compartment, a cell, a tissue or a whole 
living organism (Figeys, 2004). Lastly, metabolomics,  have also been proposed 
(Nicholson et al., 1999)to analyze concurrently all the small intermediate or final 
metabolites produced by chemical reactions taking place in cells or whole organisms.  
Metabolomics can potentially identify all the changes in biochemical composition and 
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metabolism  occuring after exposure to a given substance (Nicholson et al., 1999; 
Bugrim et al., 2004; Madalinski et al, 2009). All these “omic” approaches can 
therefore help understanding how a substance acts, at various levels, on an 
organism.  
In our previous work, we showed that hepatocytes grown in microfluidic 
biochip maintain the activity of their main enzymes for xenobiotic metabolism 
(CYP1A, CYP2B, CYP3A4, several SULT and UGT sub-families and various phase 3 
transporters such as MDR1 and MRP2) (Prot et al., 2011a, 2011b). In a study of the 
well-known hepatotoxic drug acetaminophen (APAP) in HepG2/C3a cells, we 
demonstrated that the use of biochips helps reproduce some of its in vivo reported 
mechanism of toxicity, such as GSH depletion and mitochondrial damage (Prot et al., 
2011c). To investigate the potential of integrating systems biology and microfluidic 
biochip technology, we present here the interaction between the transcriptomic, 
proteomic and metabolomic profiles of liver cells cultivated in a microfluidic PDMS 
biochip and exposed to APAP. From the integration of those profiles we identified the 
activation some liver specific pathways related to drug metabolism.  On the basis of 
our previous work we chose to work at 1mM APAP, a concentration at which 
perturbations of cell proliferation and hepatic metabolism are detectable (Prot et al., 
2011b). APAP is metabolized by the cytochromes P450  CYP2E1, CYP1A2 and CYP 
3A4. Secondary metabolism is mediated by  glutathione (GSH), sulfo and glucurono 
conjugations. Thanks to the microfluidic culture conditions, we were able to identify 
the major biological pathways involved in APAP toxicity to hepatocytes. Comparison 
with published in vivo studies finally lead to a similar interpretation of APAP toxicity 
mechanism, as opposed to the results that we obtained from the conventional plate 
analysis. 
 
RESULTS AND DISCUSSION 
 
Transcriptomic, proteomic and metabolomic analyses in microfluidic liver 
biochips  
 
HepG2/C3A cell cultures in biochips were performed as  described by Prot et 
al. (2011b). The morphology of adherent cells after 24h at rest in the biochip is 
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presented in Figures1A to 1C). After flow perfusion was started, cells proliferated 
inside the biochip during 96h the 72h of perfusion (Fig.1D). As expected, the cells 
first created a confluent monolayer at the bottom of the culture micro-chambers. 
Afterwards, the cells proliferated up over the microstructures of the biochip forming a 
multilayer tissue (Fig. 1E). Calcein AM staining demonstrated the cell viability at the 
end of the cultures (Fig. 1F). After 1mM APAP treatment for 72h, the number of cells 
was reduced when compared to the untreated conditions in both biochips and plates 
(Figs 1G and 1H). This reduction was higher in biochips than in plates (Figs. 1G and 
1H). 
 The statistical analysis of transcriptomic data discriminated global gene 
expression by separating the plate from the biochip groups for both untreated and 
treated APAP conditions (Fig 1I). Culture in the microenvironment led to a total of 
4012 genes showing statistically significant differences in expression (supplemental 
Table 1). APAP treatment in plate and in biochip significantly affected 1890 and 1121 
genes respectively (supplemental Tables 2 and 3). 
 Proteomic analysis identified 86 proteins showing significant differences in 
concentration between the plate and biochip culture conditions, without APAP 
treatment (supplemental Table 4). At the protein level,  APAP treatment had a 
statistically significant effect only in biochips, with  27 proteins affected (Fig 1J, 
supplemental Tables 5 and 6).  
Finally, the cell media were collected and analyzed by 1H NMR spectroscopy. 
40 compounds were identified from the analysis of the NMR spectra (Table 1). That  
analysis was completed with measurements of albumin, urea, glucose, glutamine 
and ammonia levels  by conventional bio-assays.  
 
Mechanistic interpretation of the effects of microfluidic cultures on HepG2/C3A 
cells without APAP treatment 
 
Knowledge-based metabolic pathway databases can be used to reveal the 
higher-order systemic operation of cells, organs and whole organisms. We identified  
significantly perturbed metabolic pathways by mapping transcriptomic, proteomic and 
metabolomic data signatures using the KEGG database (Kanehisa et al., 2010) and 
Ingenuity canonical pathways (Ingenuity® Systems). 
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At first, integration between transcriptomic, proteomic and metabolomic data 
revealed an environmental effect due to the microfluidic culture conditions. We found 
an early adaptive response via the induction of Nrf-2 pathway. According to the 
Ingenuity pathway analysis (IPA), that pathway reached a p-value of 4x10-8. Nrf-2 is a 
key transcriptional factor involved in the regulation of genes implied in  cytoprotection 
against xenobiotic and oxidative injuries. In the liver, Nrf-2 activation lead to the 
induction of several genes and proteins regulating phase 1 andphase 2 
biotransformation enzymes and phase 3 transporters. Network reconstruction, based 
on the direct links and the common elements of the metabolic canonical pathways, 
illustrates the activation of Nrf-2 dependent pathways such as glutathione and 
methionine metabolism.We also found a higher consumption of histidine and 
methionine in biochips compared to plate cultures. A complete network was built 
using the pathways' common genes, proteins and metabolites as bridges (Fig. 2, 
Table 2). Our previous work has shown thatnecrosis and apoptosis occurred only to 
a small extent in the biochips (Prot et al. 2011a).   
 
The fatty acid and lipid metabolism pathways were also highlighted by the 
profile integration via PPAR signaling, and butanoate and ketone metabolism (Fig. 3, 
Table 2) in coherence with numerous literature reports (Chapman, 2003; Cullingford 
et al., 2002). Steroids and cholesterol biosynthesis were also induced via the RXR 
and PXR pathways (Fig. 3, Table 2). However, biliary metabolism was not activated 
in our biochip cultures. Using the IPA, lipid metabolism perturbation reached a p-
value of 6x10-7, with 140 genes involved. A specific biomarker of the fatty acid and 
lipid metabolism pathways induction in biochip, was the consistently high production 
of  3-hydroxybutyrate in the culture media. 
 
Adaptation of the cell to the biochip microenvironment implies a high energy 
demand (Fig. 4, Table 2). Our analyses have shown an increase in glycolysis and 
glucogenesis. At the metabic level, we found higher glucose and glutamine 
consumptions correlated with higher ammonia , lactate, and glutamate productions. 
In addition,  butanoate metabolism, an alternative energy source (ketones are 
generated by hepatic fatty acid β-oxidation when plasma insulin or insulin/glucagon 
ratios are low) (Fukao et al., 2004), was increased in the biochip . Butanoate 
metabolism is linked to the entry in the TCA cycle via succinate and Acetyl CoA 
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productions (Table 2, Fig. 3 and 4). The degradation of several amino acids and 
metabolites (e.g., for  choline, isoleucine, leucine, tyrosine and valine, Table 1) 
illustrated the request for TCA substrates. Interestingly, both lipid and glucose 
homeostasis were correlated in biochips with an induction of the insulin pathway, 
consistently with literature reports (Stephen et al., 1991; Yu et al., 2008). Thus, lipid 
metabolism was related to gene PI3KR controlling ACACA and FASN (upregulated 
and inducing lipogenesis) and controlling PDE3B (upregulated and repressing  
lipolysis). Glucose homeostasis was related to genes CBL, C3G, TC10 and EXO70, 
linked to glucose transporters and complexes  involved in glucose uptake (Stephen 
et al., 1991).  
 
In summary, intracellular analysis via the transcriptomic and proteomic profiles 
has shown that HepG2/C3A cells adapt to their new environment by inducing a 
cytoprotective mechanism, which induces a high energy demand. The extracellular 
biomarkers identified (such as the 3-hydroxybutyrate) in microfluidic biochip cultures 
confirmed both the cytoprotective response and the energy demand. In the following 
section, we will use this cellular stimulation for  toxicity analysis. 
 
Mechanistic interpretations of the effects of APAP treatment on HepG2/C3A 
cells cultivated in microfluidic biochips 
 
The results of our study led to a mechanistic interpretation of  APAP toxicity in 
biochips. In order to demonstrate the interest of our microfluidic model and its 
relevance to predictive toxicology, we have characterized the 1mM-APAP 
transcriptomic, proteomic metabolomic profiles in our liver biochips. APAP toxic 
metabolite NAPQI (N-acetyl-p-benzoquinone imine) is trapped by glutathione and 
excreted by the cells as  GSH-APAP. That metabolites was detected by MS/MS in 
the biochip culture medium only and not in plate cultures (Table 1). Detoxification by 
sulfo-conjugation was evidenced by a higher production rate of Sult-APAP in biochips 
compared to plate cultures (Table 1). APAP pathway reconstruction using the 
integration of the transcriptomic, proteomic and metabolomics profiles led to the 
identification of a toxicity mechanism in  biochips (Fig 5). Comparison the results 
obtained in biochips with and without APAP treatment, showed that APAP injury 
affected two pathways which were not detected in plates: 
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- Lipid metabolism and peroxidation, p-value of 9.9 10-4, (via induction of the 
genes FAAH, PLA2G15, PPARD, DEGS1, FADS1, ACSBG1, ACSL1, AQP7, PASK, 
SMPD1, GPX2 , GPX3, and the production of lta4h protein); 
-Calcium homeostasis via the VDR/RXR activation pathway: p-value of 8x10-2 
(illustrated at the gene level through NCOR2, HSD17B2, NC0A1, HES1, PPARD and 
via the level of annexin A7, a calcium-dependent phospholipid binding protein, visinin 
and S100P in the proteome). 
 
In addition we found that, compared to untreated cases,APAP treatment led to 
- DNA damage: pvalue 4.4x10-4 (33 genes) 
- Cell cycle arrest p-value 1x10-5 (68 genes including SMAD3, SMAD7, p21)  
- Cell death via apoptosis and necrosis, p-value 9.9x10-4 (11 genes including 
casp 3 at the protein level)  
- Reorganization of the cytoskeleton at the protein level via  coronin, actin, 
keratin, tubulin perturbation. 
 
Thus, we confirm that in biochips the specific signature of APAP toxicity at the 
gene and protein levels  shows mechanisms similar to those reported in vivo (Ruepp 
et al., 2002). Furthermore, the APAP toxicity signaling pathway we reconstructed for 
biochips appears similar to the one built after in vivo data analysis, as shown by the 
comparison of Figs. 5 and 6. To confirm the pathway reconstruction, we specifically 
analyzed mitochondrial membrane potential perturbation. The dissipation of the 
mitochondrial electrochemical potential gradient (ΔΨ) and  mitochondrial dysfunction 
following APAP treatment was confirmed by JC-1 staining, illustrating APAP toxicity 
after 24h of perfusion (Fig 7). In addition, the higher sensitivity of cells in biochip,  
compared to plate culture conditions, was confirmed by cell counts and measures of 
cell cycle reparation in our previous work (Prot et al., 2011c).  
 
Identification of specific APAP toxicity biomarkers in biochips 
 
The results of metabolomic profiling led to the identification of specific 
biomarkers of the APAP injury related to hepatotoxicity and glutathione depletion. 
Table 1 shows the production and consumption of the molecules detected in the 
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culture medium. Using those data we were able to reconstruct a network of pathways 
of glutathione depletion in biochips (Fig 8). 
APAP injury is related to glutathione consumption and depletion via the 
formation of NAPQI. The  cellular adaptation step to the micro-environment induced 
defense mechanism involving cytochrome P450. APAP biotransformation is 
thereforeenhanced in  biochips, leading to a higher level of NAPQI production when 
compared to plate cultures. The specific augmentation of 2-hydroxybutyrate 
production and consumption of  cysteine, histidine and methionine in biochips  are 
directly correlated with the glutathione pathway and APAP detoxification mechanism. 
2-hydroxybutyrate, under metabolic stress, is released as a byproduct when 
cystathionine is cleaved to cysteine before its incorporation into glutathione (Gall et 
al. 2010). Furthermore, the glutathione precursor S-adenosylmethionine (SAM) is 
formed by combining methionine with ATP to synthesize cysteine, which is used to 
produce glutathione. The higher level of those compounds in the APAP treated 
biochips culture medium  demonstrated a higher APAP toxicity in microfluidic 
conditions. However, we did not find any taurine, creatine or ophtalmic acid 
accumulation in the culture media of the biochips. Those molecules, related to 
glutathione production, were detected in urine analysis and in liver extracts from in 
vivo studies. They have also been reported as APAP toxicity biomarkers (Beger et al. 
2010; Soga et al., 2006). 
Furthermore, increased levels of 3-hydroxybutyrate in the APAP treated 
biochip cultures demonstrated an intense lipid metabolism through the ketone 
degradation pathway. Major changes in 3-hydroxybutyrate concentration, related to 
the metabolism of plasma lipids, occurs when tissue are exposed to stress (Fukao et 
al., 2004). A high increase of urinary 3-hydroxybutyrate has been reported as an 
early biomarker of toxicity  (such as in nephrotoxicity, Boudonck et al., 2009, or 
during surgical trauma, Teague et al., 2007).  
In addition to the metabolomic biomarkers reported in Fig.8 and Table 1, the 
activation of glutathione pathway in the APAP treated biochips was correlated with 
the induction of the GGT7, G6PD, GPX2, GPX3, GSTm2/4, GSTT2 genes and by the 
g6pd and txnrd1 protein production compared to untreated biochips. We also found a 
modification of CBS, DAO, GATM, BDMGTH, SHMT gene expressions and of the 
strap and pp2ca proteins in the serine, glycine and threonine pathway; and a 
modification of the level of expression of the GATM, DAO, P4HA, PYCR, PRODH2 
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genes in the arginine-proline pathway. Amino acid biotransformation results in an 
intense TCA cycle activation (Fig 8). That was illustrated by an important 
consumption of glutamine, glucose, fructose and pyruvate, coupled with ammonium 
and lactate production when compared to untreated cultures. Correlation between 
metabolomic and transcriptomic profiles in APAP toxicity has been reported in vivo 
using mouse in which APAP affected the lipid content and glucose homeostasis, and 
were correlated to changes in liver energy metabolism (Coen et al., 2004). Our 
findings are consistent with these in vivo observations. 
 
Our results demonstrated an intense activity of the glutathione pathway due to 
glutathione depletion for NAPQI elimination. That was in agreement with GSH-APAP 
conjugation found only in biochip (Table 1). Biomarkers of the metabolic status of 
HepG2/C3A cells in microfluidic biochips were identified. They confirmed the 
detoxification processes and the related energy demand pointed at by the 
transcriptomic and proteomic analysis. That result is essential as it demonstrates the 
potential of microfluidic biochips coupled to metabolomics to provide a functional cell 
response in agreement with the intracellular information obtained at the gene and 
protein levels. We believe that the microfluidic biochip can behave as a “biosensor” 
system when combined with 1H NMR-based metabolomic footprinting of organ 
culture media, and that it will be useful as a high-throughput small-molecule 
screening approach.  
 
Systems biology and predictive toxicology on chip. 
 
To understand the mechanisms connecting molecular and cellular changes to 
tissue level properties, microarray analyses of large scale changes in gene 
expression can be studied, as shown in the present work. A significant focus of such 
studies is to discover how individual genes are integrated into specific regulatory or 
signaling networks and which pathways are significantly altered by treatments. 
However, static lists of differentially expressed genes, proteins or molecules will not 
give us a complete access to a systemic and dynamic understanding of physiological 
processes or of toxicity. Yet, we should aim for such an understanding if we want to 
replace in vivo experiments by a mechanistic and predictive toxicology (Chiu et al., 
2010). Mathematical descriptions of the liver cells and tissue, coupled to 
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physiologically based pharmacokinetic modeling (Ierapetritou et al., 2009; Park et al., 
2010), have the potential to integrate liver biochip cellomic data for a quantitative, 
dynamic and hierarchical description of the body handling of endogenous and 
exogenous substances. A shorter term goal is to develop methods for checking the 
consistency of individual pathways activations. For example, our results point to the 
activation of multiple metabolic pathways (such as drug and lipid metabolism related 
pathways and the glutathione pathway), but those were assessed individually and 
semi-quantitatively. A validation of the quantitative coherence of these findings would 
require pathways linking and an understanding (at least partial) of the sign of the 
interactions between pathway nodes. We are currently working on both of those 
short-term and long-term goals. 
Alternative methods for predictive toxicology should first be standardized and 
validated to become acceptable to regulatory authorities. In terms of molecular 
phenotyping, the comprehensive analysis of endogenous low molecular-weight 
metabolites, or metabonomics (Nicholson et al., 1999; 2002), is a powerful tool for 
characterizing  variations in the concentration of such compounds in biofluids or 
organs in response to drug treatments (Clayton et al., 2006), but also to 
pathophysiology (Dumas et al., 2006) or genetic polymorphisms (Dumas et al., 
2007). Our results demonstrate that we were able to extract specific signatures of the 
culture mode and cellular environment  in plates and in biochips. Furthermore, in vivo 
hepatotoxic and GSH depletion related biomarkers were identified in the APAP 
treated biochip cultures. Despite  the fact that we did not work with primary 
hepatocytes which would probably  better reflect  in vivo toxicity , our results are 
encouraging for an eventual application of liver microfluidic biochips as a new tool in 
xenobiotic screening applications.  
 
Conclusion 
 
In summary, we have characterized the transcriptomic, proteomic and 
metabolomic profiles of HepG2/C3A cells cultivated in a microfluidic environment. 
Profile integration demonstrated a cytoprotective cell response, induced by the 
microfluidic biochip conditions. . The toxicological response of HepG2/C3A cells in 
biochips cultures to APAP injury could be correlated to glutathione depletion and to 
the apparition of NAPQI. That led to a perturbations of calcium homeostasis via 
 13 
mitochondrial perturbations, to lipid peroxidation and to cell death. Pathway 
reconstruction resulted in a metabolic map that can be successfully superimposed to 
pathways identified from in vivo data. In addition, we also illustrated the applicability 
of an exploratory spectroscopic phenotyping assay to identify metabolic biomarkers 
of xenobiotics exposure and toxicological insults in mammalian cells thanks to 
microfluidic cultures. We found that 2-hydroxybutyrate production was a biomarker of 
APAP treatment in our study. It was correlated with a high production of 3-
hydroxybutyrate and with a high consumption of cystine, histidine and methionine in 
the treated biochips. The “systems biology on chip’ approach we propose has the 
potential to allow serendipitous discovery of cell-specific dose-response markers, 
while reducing the use of laboratory animals. Finally, our finding provide an important 
insight into the use of microfluidic biochips as new tools in biomarker research in 
therapeutic drug studies and predictive toxicity investigations.
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MATERIALS AND METHODS SECTION:  
 
Microfluidic Biochip and cell cultures. 
 
To fabricate the biochips, we used the Polydimethylsiloxane polymer (PDMS) 
(Dow Corning, Sylgard 184). This material has high gas permeability, which allows 
oxygenation of cells in culture. PDMS is transparent, and the biochips allow optical 
observations coupled with real time analysis of the cells' morphology. The fabrication 
details, based on replica molding and PDMS plasma bonding, are reported in 
Baudoin et al. (2011). 
 The hepatocellular carcinoma-derived cell lines HepG2/C3A were used as 
liver cell models. The cells were chosen for to their more stable morphotype  
compared to primary cells. That helps for parallel studies needed for biological 
characterization. The cells were maintained in a culture medium containing Minimal 
Essential Medium (MEM, Gibco), 2 mM L-Glutamine, 0.1mM non-essential amino 
acids, 1.0 mM sodium pyruvate, 10% of fetal bovine serum, and penicillin-
streptomicin (100 units/mL). The batch cultures were performed in T75 flasks 
(Falcon, Merk Eurolab, Strasbourg, France) using 15 mL of medium. The cells were 
used between the 10th and 30th passages.  
The biochips were coated with fibronectin for 40 min (10 µg/mL) before 
carrying out the cultures. The cells were cultivated in the biochips under static 
conditions during 24 h for adhesion. Then, a flow rate of 10 µL/min of medium was 
applied for 72 h. All dynamic experiments were performed within those 96 h of 
cultures.  
We compared cellular activity between the biochips and 12-well tissue culture 
plates (Becton Dickinson, Petri static conditions). Those  plates were first covered by 
0.5 mL of PDMS and then coated with fibronectin as were the biochips .  
 The cells were seeded at a density of 2.5x105 cells/cm2 in plates and in 
biochips (this corresponds to 5x105 cells/biochip). For APAP treatment , 1 mM of 
APAP was loaded in the biochip circuit and plates before the start of perfusion.  
 
RNA extraction, hybridisation on Affymetrix chips and microarray analyses 
 
We have precisely describedthe microarray procedure  in Prot et al. (2011a). 
Briefly, after RNA extraction, quality was checked with a Bioanalyzer 2100 (Agilent 
Technologies, Massy, France). RIN were ranging between 9.3 and 10. The raw data 
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(affymetrix .cel files) were obtained using affymetrix Genechip operating software. All 
.cel files were analysed using the expression console from affymetrix in order to 
monitor the microarray quality with different control metrics. Data were normalised by 
Robust Multichip Averaging  (RMA) in order to remove handling errors. A principal 
component analysis (PCA) was applied to the global expression data using the R 
software (http://www.R-project.org). Lists of the genes extracted after t-test 
separation at the 0.01 p-value. The corresponding lists were fed to Ingenuity 
Pathway Analysis to obtain biological functions, top network and gene ID. In the 
present analysis,no (???)  fold change filtration was done (on contrary to our 
previous analysis using this set of data). The GEO access of the data is GSE27420. 
 
Proteomic analysis 
 
The detailed protocol of the proteomic procedure was presented  previously  
(Prot et al., 2011c). Briefly, the cells were collected and the protein concentration 
determined by a Bradford method. The proteins were labelled with a CyDye DIGE 
fluor kit. Equilibrated strips were placed onto homemade polyacrylamide gels (8-
18%), overlaid with agarose solution and electrophoresis was performed 
simultaneously in a Ettan-DALT II system (GE Healthcare) at 2.5W/gel at 15°C until 
the bromophenol blue dye reached the bottom of the gels. Gels were scanned using 
a Typhoon 9400 (GE Healthcare) with a resolution set at 100µm. Image analysis 
were performed by Decyder software suite (GE Healthcare, version 5.02) which allow 
the comparison of the different combination corresponding to the experimental 
conditions. 
 Spots of interest was analysed using a MALDI-TOF-TOF 4800 mass 
spectrometer (Applied Biosystems). Database searching was carried out using 
Mascot version 2.2 (MatrixScience, London, UK) via the GPS explorer software (ABI) 
version 3.6 combining MS and MS/MS interrogations on Human proteins from 
Swissprot databank, 18138 entries, (Swissprot databank: 333445 sequences; 
120048673 residues, www.expasy.org). Positive identification was based on a 
Mascot score above the significance level (i.e. <5%). The reported proteins were 
always those with the highest number of peptide matches. 
Down or up-expressed proteins of the different experimental conditions 
(microfluidic biochip, plates) were retained if protein spot fold change was larger than 
+1.5 or smaller than –1.5 and had a Student’s t-test p-value less than 0.05. PCA was 
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performed on the global proteins distribution to see change of repartition according 
the experimental conditions. 
 
 
1H NMR spectroscopy of cell media. 
 
Culture media samples were prepared using 350 l of cell medium mixed 
with 200 l of a phosphate buffer pH 7.4 (50% D2O/H2O (vol/vol), 1 mM trimethylsilyl 
propionate-d4 (TSP)). All NMR experiments were carried out on a Bruker Avance III 
spectrometer operating at 800 MHz (1H resonance frequency) using a standard 5-
mm TXI probe at 300 K. Conventional 1H 1D NMR spectra were measured using the 
NOESY pulse sequence with water presaturation during the 2s recycle delay, and a 
100ms mixing time. For each sample, 128 free induction decay (FID) were collected 
with 40,960 data points with an acquisition time of 1,7 s. The FIDs were multiplied by 
an exponential weighting function corresponding to a line broadening of 0.3Hz and 
zero-filled before Fourier transformation, zero order phase correction and manual 
baseline adjustment. 
NMR metabolites assignment and quantification 
 
Identification of the metabolites from the culture medium  was carried out from 
the 1D NMR data using the software Chenomx NMR Suite 7.0 (Chenomx Inc., 
Edmonton, Canada). Assignment of additional observed metabolites was confirmed 
from the analysis of 2D 1H-1H TOCSY and 1H-13C HSQC NMR spectra recorded with 
standard parameters. Metabolites concentrations were determined by manual fitting 
of the proton resonance lines for the compounds available in the Chenomx database. 
The TSP linewidth used in the reference database was adjusted to the width of one 
component of the alanine doublet. The reference concentration was set after 
automatic fitting of the TSP resonance. 
 
Biochemical assays 
 
Glucose and glutamine consumption, and ammonia and albumin production, 
were measured after 96h of culture. The protocols have been described in detail   
previously  (Baudoin et al. 2011). Briefly, glucose, glutamine and ammonia 
 17 
concentrations were measured using a Konelab 20 biochemical analyzer (Thermo 
Electron Corporation). Albumin synthesis was measured by means of an ELISA 
sandwich technique (anti Human Albumin IgG, Cappel; anti Human Albumin IgG 
coupled with peroxydase, Cappel). The JC-1 Mitochondrial Membrane Potential Kit 
was used as an indicator of cell death according to the manufacturer’s instructions in 
order to assess the ΔΨ mitochondrial gradient and mitochondrial dysfunction. 
Valinomycin, which dissipates the mitochondrial potential, was used as a positive 
control. The red aggregated JC-1 represents intact mitochondria and the green 
fluorescence of the monomeric JC-1 represents disrupted mitochondria. The ratio of 
red to green fluorescent intensity was quantified with the CellProfiler software 
(Carpenter et al., 2006). 
 
APAP Metabolism activities 
 
APAP metabolites were measured by LC/MS/MS. The method is introduced in 
our previous work (Prot et al., 2011c). Our LC-MS/MS system is composed of Dionex 
Ultimate 3000 capillary HPLC with a Famos injector and a UV UVD 3000 detector. 
The HPLC chain is coupled with a Triple Quad WATERS (micromass) Quatro micro 
mass spectrometer. The analytes were detected by MRM (Multiple Reaction 
Monitoring) in positive ion mode. The areas obtained for Glutathione-APAP (MW: 
457g/mol), Glucurono-APAP (MW: 328 g/mol), and Sulfo-APAP (MW: 232 g/mol) 
were compared to a known quantity of each standard (SIGMA) making possible a 
semi-quantitative dosage. 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
Jean Matthieu Prot received a grant from the CNRS and from the “conseil régional de 
Picardie”. The project was supported by the foundation of the University of 
Technology of Compiègne “La Fondation UTC pour l’innovation” via the “puce à 
cellule project”. The project was also supported by the ANR PCV 2007 program via 
the “µHepaReTox” project and by the ANR CP2D 2007 program via the SysBioX 
project. The SULT-APAP and GSH-APAP was measured by Geoffrey Madalinski and 
Eric Ezan from CEA Saclay, laboratoire d’étude du métabolisme du médicament. The 
microarrays of the transcriptomic analysis were performed by Franck Letourneur from 
Institut Cochin, Paris. The proteomic analysis was supervised by Philippe Chafey at 
the Institut Cochin, Paris. We finally thank Morgane Le Gall and Guilhem Clary from 
Plateforme Electrophorese Bidimensionnelle, UMR 8104, for their technical support 
in 2D Dige analysis. 
 
 
AUTHORS CONTRIBUTIONS 
 
Jean Matthieu Prot was performed the liver biochip experiments and data analysis as 
part of his Ph.D. thesis work.  
Leila choucha Snouber was involved in some of the biochip experiments. 
Andrei Bunescu, Benedicte Elena-Hermann, Marc Emmanuel Dumas were involved 
in the metabolomic analysis. 
Anne Corlu and Caroline Aninat were involved in the transcriptomic analysis and in 
the liver biology analysis. 
Céline Brochot and Frederic Bois were involved in the data analysis. 
Laurent Griscom and Florence Razan were involved in the biochip fabrication. 
 19 
Eric Leclerc was project leader. 
All authors contributed to the paper redaction. 
 
 
CONFLICTS OF INTERESTS 
 
The authors have no conflict of interest to report.. 
 
 
REFERENCES 
 
Baudoin R, Corlu A, Griscom L, Legallais C, Leclerc E (2007) Trends in the 
development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicology in vitro 
21:535-544  
Baudoin R, Griscom L, Prot JM, Legallais C , Leclerc E (2011) Behavior of 
HepG2/C3A cell cultures in a microfluidic bioreactor, Biochemical Engineering 
Journal, 53:172–181 
Beger R, Sun J, Schnackenberg L (2010) Metabolomics Approaches for Discovering 
Biomarkers of Drug-induced Hepatotoxicity and Nephrotoxicity. Toxicology and 
Applied Pharmacology 243:154–166 
Bhogal N, Grindon C, Combes R, Balls M (2005) Toxicity testing: creating a 
revolution based on new technologies. Trends in biotechnology. 23:299-307. 
Blaauboer BJ, Andersen ME. (2007) The need for a new toxicity testing and risk 
analysis paradigm to implement REACH or any other large scale testing initiative. 
Archives of toxicology 81:385-7. 
Boudonck K, Mitchell M, Nemet L, Keresztes L, Nyska A, Shinar D, Rosenstock M, 
(2009) Discovery of Metabolomics Biomarkers for Early Detection of Nephrotoxicity, 
Toxicologic Pathology 37: 280-292 
Boverhof DR, Burgoon LD, Tashiro C, Sharratt B, Chittim B, Harkema JR, et al. 
(2006) Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in 
Sprague Dawley rats and C57BL/6 mice Toxicol Sci. 94:398-416. 
Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, 
Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM (2006) CellProfiler: image 
analysis software for identifying and quantifying cell phenotypes. Genome Biology 
7:100-111 
 20 
Chao P, Maguire T, Novik E, Cheng KC, and Yarmush ML (2009) Evaluation of a 
microfluidic based cell culture platform with primary human hepatocytes for the 
prediction of hepatic clearance in human, Biochemical pharmacology 78:625-632 
Chapman MJ (2003) Fibrates in 2003: therapeutic action in atherogenic 
dyslipidaemia and future perspectives. Atherosclerosis 171:1-13. 
Chiu WA, Euling SY, Siegel Scott C, Subramaniam RP (2010) Approaches to 
advancing quantitative human health risk assessment of environmental chemicals in 
the post genomic era, Toxicology and Applied Pharmacology, in press 
Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug 
treatment. Nature 440, 1073-1077 (2006).  
Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID (2004) 
Integrated application of transcriptomics and metabonomics yields new insight into 
the toxicity due to paracetamol in the mouse. Journal of Pharmaceutical and 
Biomedical Analysis 35:93-105. 
Cullingford TE, Dolphin CT and Sato H (2002) The peroxisome proliferator-activated 
receptor alpha-selective activator ciprofibrate upregulates expression of genes 
encoding fatty acid oxidation and ketogenesis enzymes in rat brain. 
Neuropharmacology 42:724-730. 
De Bartolo L, Bader A (2001) Review of a flat membrane bioreactor as a bioartificial 
liver. Ann. Transplant. 6:40–46 
De Kanter R, Monshouwer M, Meijer D, Groothuis G. (2002) Precision-cut organ 
slices as a tool to study toxicity and metabolism of xenobiotics with special reference 
to non-hepatic tissues. Adapt. Curr. Drug Metabol. 3:39–59. 
Dumas, M.E. et al. (2006) Metabolic profiling reveals a contribution of gut microbiota 
to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 103: 
12511-12516  
Dumas, M.E. et al. (2007) Direct quantitative trait locus mapping of mammalian 
metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet 39:666-
672  
Fiehn O, Kopka J, Dörmann P, Altmann T, Trethewey RN, Willmitzer L (2000) 
Metabolite profiling for plant functional genomics. Nat. Biotechnol. 18, 1157-1161  
Figeys D (2004) Combining different 'omics' technologies to map and validate 
protein-protein interactions in humans. Briefings in functional genomics & proteomics 
2:357-65. 
Franklin MR, Yost GS. (2000) Biotransformation: a balance between bioactivation 
and detoxification. In: Williams, P.L., James, R.C., Roberts, S.M. (Eds.), Principles of 
 21 
Toxicology: Environmental and Industrial Applications. John Wiley & Sons, New 
York, NY, 57–86 
Fukao T, Lopaschuk GD and Mitchell GA (2004) Pathways and control of ketone 
body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent 
Fatty Acids 70:243-251. 
Gall W, Beebe K, Lawton K, Adam KP, Mitchell M, Nakhle P, Ryals J, Milburn M, 
Nannipieri M, Camastra S, Natali A, Ferrannini E, (2010) a-Hydroxybutyrate Is an 
Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic 
Population, PLoS One 5:e10883  
Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, Schmelzer 
E, Ullrich M, Utesch D, Hewitt N, Ringel M, Hilz BR, Bader A, Langsch A, Koose T, 
Burger HJ, Maas J, Oesch F. (2003). New hepatocyte in vitro systems for drug 
metabolism: metabolic capacity and recommendations for application in basic 
research and drug development, standard operation procedures. Drug Metab Rev. 
35:145-213 
Ghanem, A. and Shuler, M. L. (2000). "Combining cell culture analogue reactor 
designs and PBPK models to probe mechanisms of naphthalene toxicity." 
Biotechnology Progress 16: 334-345. 
Gibney M, Walsh M, Brennan L, Roche H, German B and van Ommen B. (2005) 
Metabolomics in human nutrition: opportunities and challenges, American Journal of 
Clinical Nutrition, 82, 497-503 
Hengstler, J. G., Foth, H., Kahl, R., Kramer, P. J., Lilienblum, W., Schulz, T. and 
Schweinfurth, H. (2006). The REACH concept and its impact on toxicological 
sciences. Toxicology 220: 232-239. 
Greim H, Arand M, Autrup H, Bolt HM, Bridges J, Dybing E, Glomot R, Foa V, 
Schulte-Hermann R (2006) Toxicological comments to the discussion about REACH 
Arch. Toxicol., 80: 121-124.  
Guillouzo A. (1998) Liver cell models in in vitro toxicology. Environ Health Respect. 
106:511-532 
Guillouzo A. (2008) New perspectives in the use of human hepatocytes in the 
preclinical drug development process. Ann Pharm Fr. 66:288-295 
Griffith L and Naughton G (2002) Tissue Engineering–current challenges and 
expanding opportunities, Science 295:1009-1014 
Hartung T and Rovida C, (2009) Chemical regulators have overreached, Nature 460: 
1080-1081 
Ierapetritou MG, Georgopoulos PG, Roth CM, Androulakis IP (2009) Tissue-Level 
 22 
Modeling of Xenobiotic Metabolism in Liver: An Emerging Tool for Enabling Clinical 
Translational Research. Clinical and Translational Science 2: 228-237. 
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., and Hirakawa, M (2010) KEGG 
for representation and analysis of molecular networks involving diseases and drugs. 
Nucleic Acids Res. 38: 355-360. 
Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML (2010) A microfluidic hepatic 
coculture platform for cell-based drug metabolism studies. Biochemical 
Pharmacology 79:1036-1044. 
Nicholson JK., Connelly J, Lindon JC and Holmes E (2002) Metabonomics: a 
platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1:153-161 
Nicholson JK, Lindon JC and Holmes E (1999) ‘Metabonomics': understanding the 
metabolic responses of living systems to pathophysiological stimuli via multivariate 
statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181-1189 
Madalinski G, Godat E, Alves S, Lesage D, Genin E, Levi P, Labarre J, Tabet JC, 
Ezan E, Junot C. (2008) Direct introduction of biological samples into a LTQ-Orbitrap 
hybrid mass spectrometer as a tool for fast metabolome analysis. Anal Chem. 80: 
3291-303 
Park S, Kim SHJ, Ropella GEP, Robert MS, Hunt CA (2010) Tracing multiscale 
mechanisms of drug disposition in normal and diseased livers. Journal of 
Pharmacology and Experimental Therapeutics 334:124-136. 
Powers MJ, Janigan D, Wack KE, Baker, Stolz DB, Griffith L (2002) Functional 
behavior of primary Rat liver cells in a three-dimensional perfused microarray 
bioreactor. Tissue Engineering 8:499-508 
Prot JM, Aninat C, Griscom L, Razan F, Brochot C, Guguen Guillouzo C, Legallais C, 
Corlu A, Leclerc E (2011a) Improvement of HepG2/C3a cell functions in a microfluidic 
biochip, Biotechnology and Bioengineering, 108:1704-1715  
Prot JM, Videau O., Brochot C., Legallais C., Benech H., Leclerc E. (2011b), A 
cocktail of metabolic probes demonstrates the relevance of primary human 
hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening, Int J. 
of Pharmaceutics, 408: 67-75 
Prot JM, Briffaut AS, Letourneur F, Chafey P, Merlier F, Grandvalet Y, Legallais C, 
Leclerc E (2011c), Integrated proteomic and transcriptomic investigation of the 
acetaminophen toxicity in liver microfluidic biochip, PlosOne, 6, 21268- 21278 
Ruepp S., Tonge R., Shaw J., Wallis N, Pognan F (2002) Genomics and Proteomics 
Analysis of Acetaminophen Toxicity in Mouse Liver. Toxicological Sciences. 65:135-
150 
 23 
Sheikh-Bahaei S, Kim SHJ, Sheikhbahaei S, Hunt CA (2009) Understanding the Role 
of Liver Zonation in Toxin Elimination. International Journal of Intelligent Control and 
Systems 14: 33-40. 
Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson 
LD,Tannenbaum SR, Griffith LG. 2005. A Microscale In Vitro Physiological Model of 
the Liver: Predictive Screens for Drug Metabolism and Enzyme Induction. Current 
Drug Metabolism 6:569-592 
Stephens JM, Pekala PH (1991) Transcriptional repression of the GLUT4 and C/EBP 
genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha, J Biol Chem. 266:21839-
45. 
Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y, Ishikawa 
T, Robert M, Nishioka T, Tomita M (2006) Differential metabolomics reveals 
ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione 
consumption. J Biol Chem. 281:16768-76 
Son D., Satsu H., Shimizu M., (2005) Histidine inhibits oxidative stress and TNF 
alpha induced interleukin 8 secretion in intestinal epithelial cells, FEBS Letters 579, 
4661-4677 
Teague CR, Dhabhar FS, Barton RH, Beckwith-Hall B, Powell J, Cobain M, Singer B, 
McEwen BS, Lindon JC, Nicholson JK, Holmes E, (2007) Metabonomic studies on 
the physiological effects of acute and chronic psychological stress in Sprague-
Dawley rats. J. Proteome Res. 6:2080–93. 
Yu X, Pandey SK, Booten SL, Murray SF, Monia BP, Bhanot S (2008) Reduced 
adiposity and improved insulin sensitivity in obese mice with antisense suppression 
of 4E-BP2 expression, Am J Physiol Endocrinol Metab. 294:E530-9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
 
 
 
 
 
FIGURES AND TABLES LIST 
 
Table 1: Cell production (+) and consumption (-) in nmol/h/10
6
cells of the compounds detected by H-
NMR and measured in the culture medium. The data represent the situation between 48h and 96h of 
cultures in plates or biochips (mean and SD, n=3+9=12), --- denotes data below the limit of 
1
H-RMN 
detection (1µM), * denotes values measured by conventional biochemical assays and kits, ** denotes 
products detected by MS/MS; (µ) denotes arbitrary unit AU, £ denotes data in ng/h/10
6
cells 
 
Table 2: List of genes, proteins and metabolites affected by the microfluidic conditions when 
compared to plate cultures and involved in the network reconstruction of Figs 2 and 3. Underlined 
genes were confirmed by RTqPCR (Prot et al., 2011a) 
 
Figure 1: (A) Microfluidic PDMS network; (B) Cell chamber before cell inoculation; (C) Cell after 
adhesion; (D) Cell after 96h of cultures without APAP; (E) SEM view of the cell multilayers in the 
biochip after 96h of culture without APAP; (F) viability of the cells after 96h of culture without APAP ; 
(G) Cells after 96h of culture including 72h of APAP treatment; (H) Cell number decreases in biochip 
and plate with 1mM of APAP after 96h of cultures including 72h of treatment; (I) Results of the PCA of 
the transcriptomic analysis; (J) Results of the PCA of the proteomic analysis; circles denotes plate 
data, triangles denote biochip data, black symbols are control data, white symbols are APAP data. 
 
Figure 2: Network reconstruction according to the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of cultures describing the HepG2/C3A response to the microfluidic 
biochip conditions. Superscripts denote information from table 2 and extracted at (1) the genes, 
proteins and metabolites levels, (2) at the gene and protein levels, (3) at the genes and metabolites 
levels, (4) at the genes level. Reported genes, proteins and metabolites are common element used to 
bridge the pathways; upward arrows denote gene induction, protein and metabolite 
production;downward arrows denote gene down regulation, protein and metabolite consumption. 
Capital letters (e.g. CBS …) denote affected genes in the pathway, small italic letters denotes proteins 
(e.g. strap…) related to the pathway. 
 
Figure 3: Network reconstruction according the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of culture of the HepG2/C3A in microfluidic biochips focusing on the 
lipids, fatty acids and steroids metabolism. Superscripts denote information from table 2 extracted at 
(1) the genes, proteins and metabolites levels, (2) at the gene and protein levels, (3) at the genes and 
metabolites levels, (4) at the genes level. Reported genes, proteins and metabolites are common 
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element used to bridge the pathways; upward arrows denote gene induction, protein and metabolite 
production; downward arrowsdenote gene down regulation, protein and metabolite consumption.  
 
 
 
 
Figure 4: Network reconstruction according the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of culture and related to the HepG2/C3A energy demand. Superscripts 
denote information from table 2 extracted at (1) the genes, proteins and metabolites levels, (2) at the 
gene and protein levels, (3) at the gene and metabolites levels, (4) at the genes level. Reported 
genes, proteins and molecules are common element used to bridge the pathways; upward arrows 
denote gene induction, protein and metabolite production; downward arrowsdenote gene down 
regulation, protein and metabolite consumption.  
 
Figure 5: Mechanistic network reconstruction of the 1mM-APAP toxicity in the HepG2/C3a after 96h 
of culture in biochip based on the in vivo representation of Ruepp et al. 2002; Superscripts denote 
information confirmed at (1) the genes, proteins and metabolomics levels, (2) at the gene and protein 
levels, (3) at the gene and metabolomics levels, (4) at the genes level, (5) at the proteins level, (6) at 
metabolites level. Reported genes, proteins and molecules denote affected compounds or are used to 
bridge the pathways; upward arrows denote gene induction, protein and metabolite production; 
downward arrowdenote gene down regulation, protein and metabolite consumption.  
 
Figure 6: Mechanistic network of the APAP toxicity from in vivo analysis proposed by Ruepp et al. 
2002 
 
Figure 7: Mitochondrial activity analyzed by JC-1 in biochips in control and APAP treated cases after 
48h of culture; (A) Red/Green ratio; (B) fluorescent images used for the analysis 
 
Figure 8: Biomarkers network reconstruction of the 1mM-APAP toxicity in the HepG2/C3A after 96h of 
cultures in the biochips coming from the comparison between biochip controls vs APAP-treated 
biochips. Downward arrows denote metabolites consumptions; upward arrows denote metabolites 
production 
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Table 1: Cell production (+) and consumption (-) in nmol/h/10
6
cells of the compounds detected by H-
NMR and measured in the culture medium. The data represent the situation between 48h and 96h of 
cultures in plates or biochips(mean and SD, n=3+9=12), --- denotes data below the limit of 
1
H-RMN 
detection (1µM), * denotes values measured by conventional biochemical assays and kits, ** denotes 
products detected by MS/MS; (µ) denotes Arbitrary Unit AU, £ denotes data in ng/h/10
6
cells 
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Table 2: List of genes, proteins and metabolites affected by the microfluidic conditions when 
compared to plate cultures and involved in the network reconstruction of Figs 2 and 3. Underlined 
genes were confirmed by RTqPCR (Prot et al., 2011a) 
 
 
 
Compounds Plate conditions Biochip conditions 
Control APAP-1mM Control APAP-1mM 
2-Hydroxybutyrate 0,5±0.05 0,55±0.06 0,6±0.2 1,8±0.5 
3-Hydroxybutyrate 0,03±0.03 0,040±0.07 2±1.8 5±3 
3-Methyl-2-oxovalerate 0.5±0.07 0.5±0.07 0.7±0.3 1.5±0.3 
Acetate --- --- 2,4±1.2 3±1 
Alanine 29±3 49±5 7±2 35±7 
Albumin *
£ 
71±12 140±30 78±25 140±40 
Ammoniac * 37±8  46±22  
Arginine -16±19 -21,3±26 -16±5 -43±12 
Asparagine -2.0±0.7 -1,84±0.7 -3±0.7 -6±2 
Aspartate -1.0±0.3 -2,87±0.8 1,6±0.3 -2.0±0.3 
Choline -0,12±0.03 0,11±0.02 -0,6±0.2 -1,1±0.2 
Citrate 0,6±0.1 1,18±0.2 1,32±0.44 1,7±0.4 
Creatine -0,044±0.008 0,18±0.03 -0,25±0.04 -0,35±0.05 
Creatinine -0.11±0.03 -0.07±0.01 -0.4±0.07 -1±0.1 
Cystine -0,83±0.09 -0,82±0.09 -1,7±0.3 -4,6±1.5 
Ethylacetate 17±7 20±5 -2.8±0.4 9±3 
Formate 11±1.5 13±2 12±7 23±6 
Fructose -15±17 -14±6 -3,2±0.4 -9±1 
Glucose -160±10 -210±20 -200±14 -228±35 
Glucose * -138±20 -191±40 -172±30 -283±60 
Glutamate 6,7±0.9 6,5±0.8 17±6 31±6 
Glutamine -29±4 -35±5 -66±29 -93±23 
Glutamine * -16±5  -66±20  
Glycine 3,2±0.3 5,5±0.8 6±2 9±2 
GSH-APAP**
,µ 
--- --- --- 3±1 
Histidine -0,8±0.1 -0,35±0.04 -1,5±0.13 -2,9±0.4 
Isoleucine -4,4±0.4 -3,97±0.4 -6,6±0.4 -11,7±1.3 
Lactate 302±32 429±46 349±94 277±61 
Leucine -4,8±0.5 -5,2±0.7 -7,4±1.4 -15±3 
Lysine -0,37±0.09 0,24±0.05 -1,4±0.4 -3,1±0.5 
Methionine -0,97±0.11 -0,87±0.1 -1,8±0.2 -2,8±0.4 
Methanol 0.6±0.4 0.87±0.4 0.07±0.05 0.5±0.1 
Methylguanidine -0.5±0.1 -0.4±0.1 -1±0.3 -2.5±0.4 
myo-Inositol 0,67±0.07 1,42±0.2 -0,8±0.1 0,78±0.09 
Ornithine 9,4±1 13±3 12±10 22±16 
Phenylalanine -1,04±0.1 -1,3±0.1 -2,9±0.3 -4,3±0.5 
Proline 8,6±0.8 12,6± 6±2 12±2 
Pyroglutamate -3±0.5 -3±0.4 4±0.7 8±1 
Pyruvate -17±3 -16±4 -11±3 -48±10 
Serine 2,6±0.6 6±1 1,1±0.3 5±1 
Succinate -1,4±1.2 -1,7±1.2 0,4±0.1 -2±1 
Sult-APAP** --- 44±2 --- 77±18 
Threonine 1,31±0.16 2,54±0.2 -0,92±0.09 -2,4±0.3 
Tryptophan 0,23±0.03 0,44±0.06 0,06±0.003 0,57±0.05 
Tyrosine 0,62±0.075 2,7±0.3 -0,7±0.1 1,50±0.2 
Urea* --- --- --- --- 
UGT-APAP** --- --- --- --- 
Valine -0,34±0.03 1,6±0.2 -2,3±0.1 -3,0±0.4 
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NFR2 pathway AKR, AKT, CAT, CBR1, CYP 1A1, CYP1A2, EPHX1, 
FTH1, FTL, GCLM , GPX2, GSR, GST, HO-1, 
HSP90, KEAP1, MEK1/2, NQO1,PI3K, PRDX1, 
SOD, SQTSM1, STIP1, SULT1A, UGT, VCP, TXN 
ftl, actin, gsto1, sult1a, 
aldh1a1, g6pd, hsp90, 
pdia 
 
Actin regulation 
pathway 
ARPC, CDC42 , CFL1, GSN, PAK1/7, PI3K , 
PIP4K2B , PFN2, SSH2, VAV2, WAS , WASF2 
actin  
Glutathione 
pathway 
 
GCLM, GGT, GPX2, GSR, GST, IDH1, ODC1 PEPN gsto1, g6pd Glycine, Glutamate, 
Cystine, Ornithine 
Methionine 
pathway 
 
ADI1, AMD1, CBS, GOT2, MAT1A, MAT2B, MTAP, 
SRM 
 Cystine, Serine, 
Methionine, 2-
Hydroxybutyrate 
Serine glycine 
threonine 
pathway 
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Figure 1: (A) Microfluidic PDMS network; (B) Cell chamber before cell inoculation; (C) Cell after 
adhesion; (D) Cell after 96h of cultures without APAP; (E) SEM view of the cell multilayers in the 
biochip after 96h of culture without APAP; (F) viability of the cells after 96h of culture without APAP ; 
(G) Cells after 96h of cultures including 72h of APAP treatment; (H) Cell number decreases in biochip 
and plate with 1mM of APAP after 96h of cultures including 72h of treatment; (I) Results of the PCA of 
the transcriptomic analysis; (J) Results of the PCA of the proteomic analysis; circles denotes plate 
data, triangles denote biochip data, black symbols are control data, white symbols are APAP data 
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Figure 2: Network reconstruction according to the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of cultures describing the HepG2/C3A response to the microfluidic 
biochip conditions. Superscripts denote information from table 2 and extracted at (1) the genes, 
proteins and metabolites levels, (2) at the gene and protein levels, (3) at the genes and metabolites 
levels, (4) at the genes level. Reported genes, proteins and metabolites are common element used to 
bridge the pathways; upward arrows denote gene induction, protein and metabolite 
production;downward arrows denote gene down regulation, protein and metabolite consumption. 
Capital letters (e.g. CBS …) denote affected genes in the pathway, small italic letters denotes proteins 
(e.g. strap…) related to the pathway. 
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Figure 3: Network reconstruction according the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of culture of the HepG2/C3A in microfluidic biochips focusing on the 
lipids, fatty acids and steroids metabolism. Superscripts denote information from table 2 extracted at 
(1) the genes, proteins and metabolites levels, (2) at the gene and protein levels, (3) at the genes and 
metabolites levels, (4) at the genes level. Reported genes, proteins and metabolites are common 
element used to bridge the pathways; upward arrows denote gene induction, protein and metabolite 
production; downward arrowsdenote gene down regulation, protein and metabolite consumption.  
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Figure 4: Network reconstruction according the integration of the transcriptomic, proteomic and 
metabolomic profiles after 96h of culture and related to the HepG2/C3A energy demand. Superscripts 
denote information from table 2 extracted at (1) the genes, proteins and metabolites levels, (2) at the 
gene and protein levels, (3) at the gene and metabolites levels, (4) at the genes level. Reported 
genes, proteins and molecules are common element used to bridge the pathways; upward arrows 
denote gene induction, protein and metabolite production; downward arrowsdenote gene down 
regulation, protein and metabolite consumption.  
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Figure 5: Mechanistic network reconstruction of the 1mM-APAP toxicity in the HepG2/C3a after 96h of culture in biochip (based on the in vivo representation of 
Ruepp et al. 2002 presented in Fig 6); Superscripts denote information confirmed at (1) the genes, proteins and metabolomics levels, (2) at the gene and protein 
levels, (3) at the gene and metabolomics levels, (4) at the genes level, (5) at the proteins level, (6) at metabolites level. Reported genes, proteins and molecules 
denote affected compounds or are used to bridge the pathways; upward arrows denote gene induction, protein and metabolite production; downward arrowdenote 
gene down regulation, protein and metabolite consumption.  
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Figure 6: Mechanistic network of the APAP toxicity from in vivo analysis proposed by Ruepp et al. 2002 (figure extracted from Ruepp et al.) 
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Figure 7: Mitochondrial activity analyzed by JC-1 in biochips in control and APAP treated cases after 48h of culture; (A) Red/Green ratio; (B) fluorescent images 
used for the analysis 
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Figure 8: Biomarkers network reconstruction of the 1mM-APAP toxicity in the HepG2/C3A after 96h of cultures in the biochips coming from the comparison between 
biochip controls vs APAP-treated biochips. Downward arrows denote metabolites consumptions; upward arrows denote metabolites production 
